Form 8-K - Current report:
SEC Accession No. 0000950170-24-114690
Filing Date
2024-10-15
Accepted
2024-10-15 16:20:08
Documents
13
Period of Report
2024-10-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20241014.htm   iXBRL 8-K 57298
2 EX-99.1 ktra-ex99_1.htm EX-99.1 23054
3 GRAPHIC img40499469_0.jpg GRAPHIC 115627
  Complete submission text file 0000950170-24-114690.txt   368178

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ktra-20241014.xsd EX-101.SCH 27217
16 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20241014_htm.xml XML 4907
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

EIN.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 241372059
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)